14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $41.19 $42.86 Wednesday, 1st May 2024 CERE stock ended at $42.63. This is 0.187% less than the trading day before Tuesday, 30th Apr 2024. During the day the stock fluctuated 0.610% from a day low at $42.60 to a day high of $42.86.
90 days $40.66 $43.59
52 weeks $19.59 $43.59

Historical Cerevel Therapeutics Holdings, Inc. prices

Date Open High Low Close Volume
May 01, 2024 $42.73 $42.86 $42.60 $42.63 914 500
Apr 30, 2024 $42.57 $42.82 $42.56 $42.71 1 030 616
Apr 29, 2024 $42.49 $42.85 $42.38 $42.75 705 473
Apr 26, 2024 $42.02 $42.49 $41.94 $42.47 673 871
Apr 25, 2024 $41.81 $42.19 $41.80 $42.07 672 507
Apr 24, 2024 $41.97 $42.06 $41.87 $41.90 618 818
Apr 23, 2024 $42.10 $42.14 $41.90 $41.99 1 345 372
Apr 22, 2024 $42.28 $42.30 $41.86 $42.10 689 135
Apr 19, 2024 $42.01 $42.23 $42.00 $42.21 790 329
Apr 18, 2024 $41.88 $42.21 $41.70 $42.14 1 238 103
Apr 17, 2024 $41.47 $41.80 $41.30 $41.60 822 283
Apr 16, 2024 $41.60 $41.80 $41.19 $41.31 1 422 803
Apr 15, 2024 $41.83 $41.92 $41.54 $41.70 1 214 496
Apr 12, 2024 $42.02 $42.05 $41.50 $41.85 2 104 465
Apr 11, 2024 $42.17 $42.18 $42.00 $42.01 907 671
Apr 10, 2024 $42.10 $42.27 $42.04 $42.11 1 203 831
Apr 09, 2024 $42.20 $42.20 $42.04 $42.13 742 470
Apr 08, 2024 $42.17 $42.28 $42.10 $42.21 653 547
Apr 05, 2024 $42.15 $42.28 $42.05 $42.17 972 154
Apr 04, 2024 $42.31 $42.41 $42.16 $42.17 1 359 817
Apr 03, 2024 $42.35 $42.51 $42.16 $42.33 1 460 353
Apr 02, 2024 $42.30 $42.57 $42.28 $42.35 874 392
Apr 01, 2024 $42.25 $42.41 $42.22 $42.32 645 358
Mar 28, 2024 $42.35 $42.38 $42.11 $42.27 920 383
Mar 27, 2024 $42.36 $42.52 $42.18 $42.38 756 772
Click to get the best stock tips daily for free!

About Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings. Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as we... CERE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT